344 related articles for article (PubMed ID: 11886510)
1. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
2. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
3. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
4. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
5. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
[TBL] [Abstract][Full Text] [Related]
6. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of autoimmune vitiligo T cells.
Oyarbide-Valencia K; van den Boorn JG; Denman CJ; Li M; Carlson JM; Hernandez C; Nishimura MI; Das PK; Luiten RM; Le Poole IC
Autoimmun Rev; 2006 Aug; 5(7):486-92. PubMed ID: 16920575
[TBL] [Abstract][Full Text] [Related]
8. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
Steitz J; Brück J; Lenz J; Büchs S; Tüting T
J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
[TBL] [Abstract][Full Text] [Related]
9. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
10. Reduction of skin-homing cytotoxic T cells (CD8+ -CLA+) in patients with vitiligo.
Antelo DP; Filgueira AL; Cunha JM
Photodermatol Photoimmunol Photomed; 2011 Feb; 27(1):40-4. PubMed ID: 21198882
[TBL] [Abstract][Full Text] [Related]
11. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
Steitz J; Wenzel J; Gaffal E; Tüting T
Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
[TBL] [Abstract][Full Text] [Related]
12. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
13. Why tyrosinase for treatment of melanoma.
Song YH
Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
[No Abstract] [Full Text] [Related]
14. Autoimmune aspects of vitiligo.
Kemp EH; Waterman EA; Weetman AP
Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
[TBL] [Abstract][Full Text] [Related]
15. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells.
Lin M; Zhang BX; Shen N; Dong XJ; Zhang C; Qi XY; Zhu J; Li YZ; Man MQ; Tu CX
Eur J Dermatol; 2014; 24(6):676-82. PubMed ID: 25335433
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like primary melanoma.
Lugo-Somolinos A; Sánchez JL; Garcia ME
Am J Dermatopathol; 2008 Oct; 30(5):451-4. PubMed ID: 18806487
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
